ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care.

You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.

Save the date for ESMO 2025, taking place in Berlin, Germany 17-21 October 2025.

Wednesday, Nov. 5–Sunday, Nov. 9, 2025, at the Gaylord National Resort and Convention Center National Harbor, Md. Details TBD.

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities. Program TBD.

This meeting will explore the emerging field of immunometabolism, examining how metabolic and immune processes interact across biological scales in health and disease. Topics will include nutrient signaling, microbial metabolites, neuro-immune interactions, and the role of these mechanisms in aging and age-related diseases. By uniting experts from metabolism and immunology, the program will foster collaborations, tool-sharing, and innovative research directions. Attendees will gain fresh perspectives and practical approaches to advance their own work.

Make plans to join us again in Los Angeles for AACR IO 2026—encompassing the very best of basic, translational, and clinical research in immunology, inflammation, and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The inaugural AACR IO 2025 program attracted over 600 basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. The comprehensive and unique format included a mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits.

This meeting will bring together a diverse group of basic, translational and clinical researchers including those from academia, industry and government to cooperatively discuss the mechanistic basis of failed immunotherapy, and novel approaches to activating the immune system, in order to provide insight for future clinical applications of novel approaches and optimal combination therapies.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest not-for-profit annual meeting in Europe focused on cancer immunotherapy research and development, CIMT invites international participants for high-level scientific exchange, collaboration, and education.

Details TBD

Cochairs

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California